At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 84 enrolled
Drug / intervention
Megestrol acetate +1 moredrug
Likely dose
Megestrol acetate 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study
In Brief
A Phase 3 clinical trial evaluating Megestrol acetate and exemestane (Aromasin) for Metastatic Breast Cancer. Completed, enrolled 84 participants across 7 sites.
Detailed Summary
Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or anti-estrogens plus chemotherapy and who had participated on an original study of exemestane vs megestrol : study 971-ONC-0028-080.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2001
Primary CompletionDec 2007
Study CompletionDec 2009
First PostedNov 2010
TodayJul 2026
First PostedNov 9, 2010
Enrollment StartNov 1, 2001
Primary CompletionDec 1, 2007
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 15.6 years ago
Interventions
Megestrol acetatedrug
Megestrol Acetate 160 mg oral tablets Qd
exemestane (Aromasin)drug
exemestane (Aromasin) 25 mg oral tablets Qd